Bilaketaren emaitzak - David Back

Findu emaitzak
  1. 1
    The challenge of HIV treatment in an era of polypharmacy

    The challenge of HIV treatment in an era of polypharmacy nork David Back, Catia Marzolini

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned

    Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned nork David Back, David M. Burger

    Argitaratua 2015
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  3. 3
    New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals

    New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals nork Kay Seden, David Back, Saye Khoo

    Argitaratua 2010
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Maraviroc: Pharmacokinetics and drug Interactions

    Maraviroc: Pharmacokinetics and drug Interactions nork Sylvie Abel, David Back, Manoli Vourvahis

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes

    Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes nork Victoria A. Eagling, John Tjia, David Back

    Argitaratua 1998
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors

    Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors nork Louise Profit, Victoria A. Eagling, David Back

    Argitaratua 1999
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

    Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir nork Victoria A. Eagling, David Back, Michael Barry

    Argitaratua 1997
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Darunavir: Pharmacokinetics and Drug Interactions

    Darunavir: Pharmacokinetics and Drug Interactions nork David Back, Vanitha Sekar, Richard M. W. Hoetelmans

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid)

    Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid) nork Laura Else, Stephen Taylor, David Back, Saye Khoo

    Argitaratua 2011
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells

    Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells nork Philip Martin, R Riley, David Back, Andrew Owen

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications

    Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications nork Catia Marzolini, Sara Gibbons, Saye Khoo, David Back

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Differences in the cytochrome <i>P</i>-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α-ethinyloestradiol. Relative activities of rat and human liver enzymes

    Differences in the cytochrome <i>P</i>-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α-ethinyloestradiol. Relative activities of rat and human liver enzymes nork S. Ball, Lesley M. Forrester, C. Roland Wolf, David Back

    Argitaratua 1990
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Stopping antiretroviral therapy

    Stopping antiretroviral therapy nork Stephen Taylor, Marta Boffito, Saye Khoo, Erasmus Smit, David Back

    Argitaratua 2007
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

    Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine nork Daryl Hodge, David Back, Sara Gibbons, Saye Khoo, Catia Marzolini

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

    Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro nork Patrick G. Hoggard, Stephen Kewn, Michael Barry, Saye Khoo, David Back

    Argitaratua 1997
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients

    Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients nork Concepta Merry, Michael Barry, Fiona Mulcahy, Kathryn L. Halifax, David Back

    Argitaratua 1997
    Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine

    Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine nork Beth Williamson, Kelly E. Dooley, Yuan Zhang, David Back, Andrew Owen

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenz

    The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenz nork S Clarke, Fiona Mulcahy, John Tjia, Helen Reynolds, Sara E. Gibbons, Michael Barry, David Back

    Argitaratua 2001
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug Users

    Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug Users nork S Clarke, Fiona Mulcahy, John Tjia, Helen Reynolds, Sara E. Gibbons, Michael Barry, David Back

    Argitaratua 2001
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

    Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect nork Felix Stader, Saye Khoo, Marcel Stoeckle, David Back, Hans H. Hirsch, Manuel Battegay, Catia Marzolini

    Argitaratua 2020
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: